Unrealistic estimation of population prevalence of antiphospholipid antibody-related pregnancy loss: Comment on the article by andreoli et al

Arthritis Care and Research

Volumn 66, Issue 6, 2014, Pages 966-

  Clark, Christine A ^a   Laskin, Carl A ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ECLAMPSIA; HELLP SYNDROME; HUMAN; LETTER; MATERNAL MORBIDITY; POPULATION RESEARCH; PREECLAMPSIA; PREGNANCY OUTCOME; PREVALENCE; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MYOCARDIAL INFARCTION; PREGNANCY; PREGNANCY COMPLICATIONS; STROKE; VENOUS THROMBOSIS;

EID: 84901660606     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22273     Document Type: Letter

References (4)

1. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D, on behalf of APS Action. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65: 1869-73.
2. Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-8.
3. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428-32.
4. Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) 2014; 53: 275-84.